A traffic signal at dusk with the yellow light lit and the red and green lights off, beside the words "Not a Green Light"

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

October 21, 2026•13 min read

By Kate Dee, MD — Founder, MedSpa Board

Last week the FDA took one more small step in a long, complicated effort to let pharmacies compound peptides that have never been approved. On October 14, 2026, the Department of Health and Human Services and the FDA sent a document titled “Interim Access Policy for Compounding Using Certain Peptides” to the Office of Management and Budget for review. The filing is a one-line notice. It contains no policy text. It names no peptides. It sets out no conditions.

According to the Associated Press, two people familiar with the plan say it would let compounding pharmacies temporarily prepare some popular peptides, including BPC-157, while the FDA works on longer-term changes. That is the whole of what is known.

The reaction has not matched the facts. One wellness clinic operator who sells peptides posted on X: “This is huge.” Hims & Hers and Noom have both said they will offer peptides if federal access eases. Wall Street analysts put the market at $2 billion to $3 billion. Every medspa that offers peptides, or is thinking about it, is about to hear from a supplier that peptides are “about to be legal.”

All of that is extremely premature. A document under review is not a policy. Even if this effort succeeds, the permanent version is likely at least another year or two away. And none of it leads to FDA approval. These peptides are not going to be approved. At most, pharmacies will be allowed to compound them. If a sales rep tells you the FDA is about to approve peptides, that rep is selling, not informing.

Approved and compounded are not the same thing

An FDA-approved drug has been through controlled clinical trials in humans. A manufacturer has shown the FDA that the drug works for a specific use, at a specific dose, and that its benefits outweigh its risks. The FDA has reviewed how it is made. That process is what tells a prescriber what a drug does and what it can do to a patient.

Nothing in the current peptide process involves any of that. There are no new trials. No one is asking the FDA to review evidence that BPC-157 works. The question on the table is narrower: whether a licensed pharmacy may mix these substances for an individual patient with a prescription.

There are two ways that could happen. The first is the interim policy now under review, which would rely on enforcement discretion. That means the FDA chooses not to take action against qualifying pharmacies that compound certain peptides. It does not make any peptide an approved drug, it does not mean the FDA has evaluated the finished product, and it does not change federal law. The FDA can narrow or withdraw it at any time, without rulemaking. A policy that exists at the pleasure of one administration can end with the next one.

The second, permanent route is adding a peptide to the 503A Bulk Drug Substances List. That requires full notice-and-comment rulemaking, which has not begun for any of these peptides. Holland & Knight (lawyers specializing in healthcare and medspa law) estimates a final rule could take until 2027 or 2028. Even a peptide that makes it onto that list is still not an approved drug.

What is actually under review

The submission went to the Office of Information and Regulatory Affairs, the part of OMB that reviews significant federal regulatory actions before they are released. That review can change a policy, delay it, or narrow it. The Alliance for Pharmacy Compounding notes unconfirmed reports of a backlog of more than 50 HHS actions waiting for review. No release date has been announced.

We do not know which peptides are covered, which routes of administration, what conditions a pharmacy would have to meet, or whether the policy reaches beyond 503A pharmacies. The likely candidates are the six peptides the FDA’s Pharmacy Compounding Advisory Committee voted to recommend in July: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon. The committee voted against a seventh, emideltide, also called DSIP. None of the six is confirmed, and the final list could be shorter.

This is not being driven by science

It helps to look at who is pushing this forward, and who is not.

Beginning in 2023, the FDA placed BPC-157 and more than a dozen other injectable peptides on its list of substances that raise significant safety concerns for compounding, citing risks including contamination, allergic reactions, and tumor growth. When the advisory committee met in July, the FDA’s own staff scientists told it that none of these peptides had been studied enough to establish safety or effectiveness. Most of the available data comes from animal studies.

The committee voted to recommend six of the seven anyway. It had been reshaped weeks before the meeting. STAT reported that HHS selected many of the new panelists. TIME reported that “many of the voting members on the committee consult with or are employed by companies that could promote or dispense peptides.” We covered the details in our post on research-use-only peptides.

The pressure to move forward has come from the top. Health Secretary Robert F. Kennedy Jr. declared, before joining the administration, that “FDA’s war” on peptides would soon end, and has since said compounding pharmacies must be allowed to sell them. The compounding industry’s trade group asked the FDA for exactly this kind of interim enforcement discretion. Telehealth companies have announced they are ready to sell. The people who stand to profit are the ones at the table.

In my view, this is a process in which the scientists said “not yet,” and the people who stand to make money said “now.” Patients and providers should weigh it accordingly.

A safer supply would be a real improvement

This is not an argument against peptides. These substances are already widely used and very popular. Patients buy them online, wellness clinics stock them, and the supply chain behind most of them is completely unreliable. Right now, nobody knows what they are really getting: whether the vial contains the peptide on the label, what the dose is, or what else is in it.

The risks are concrete. A research-grade powder does not have to be sterile or tested for endotoxin, the bacterial debris that can cause fever, a dangerous drop in blood pressure, and shock. A certificate that says “99% pure” describes the peptide. It says nothing about contamination. When the government tested Paradigm Peptides’ muscle-building products, they turned out to be testosterone, and the company’s lab certificates were forged, as we covered in our post on the Paradigm Peptides case.

Moving these peptides to licensed compounding pharmacies would change that. A 503A pharmacy must use pharmaceutical-grade ingredients, compound under state pharmacy oversight and sterile compounding standards, and prepare each drug for an identified patient with a prescription. People who are already using these peptides, and who switch from gray-market vials to compounded ones, would at least know what they are injecting, at what dose, and that it was made in a sterile environment. That would make peptide use much safer.

It would not make the peptides themselves any better understood.

Who will study them?

A pure, correctly dosed vial of an unstudied drug is still an unstudied drug. Purity tells you what is in the vial. It does not tell you whether the drug works, at what dose, or what it does to the body over years of use.

It also does not tell you what the drug does across a population. A drug given to a few hundred enthusiasts can look harmless. Given to millions of people, rare side effects appear: a cancer signal, a clotting problem, an interaction with a common medication. Controlled trials and long-term follow-up exist to catch those problems.

Normally, the company that owns a drug pays for that research. Clinical trials cost enormous sums, and drug companies fund them because patents and market exclusivity let them earn the money back if the drug proves safe and effective.

These are orphan peptides. Most have been described in the scientific literature for decades and are already in the public domain. They cannot be patented, so no drug company has a reason to spend the money to study them. Compounding them does not change that.

So if these peptides are compounded, who will study them? Perhaps academic medical centers or government-funded researchers. Perhaps the compounding industry, whose trade group has asked the FDA for adverse event reporting and data collection on peptide use. Collecting reports of side effects after the fact has value, but it is not a controlled study, and it will not reveal long-term harms. The hope is that a safer supply comes first and real research follows. Until someone does that research, every patient who receives one of these peptides is part of an experiment no one is running.

What this policy will not cover

Based on the reporting and the legal analyses published so far, an interim policy built on 503A enforcement discretion would not apply to:

Research-use-only products. A vial labeled “for research use only” or “not for human consumption” is an unapproved drug the moment it is intended for a patient. This policy is about licensed pharmacies compounding from pharmaceutical-grade ingredients. It does nothing for the vial from a website, and the FDA is still sending warning letters to the sellers.

Dietary supplements. A peptide sold as a supplement is a different product with a different set of issues.

503B outsourcing facilities. A 503A policy does not automatically extend to outsourcing facilities unless the FDA says so expressly.

State law. State boards of medicine, nursing, and pharmacy still govern who may prescribe, compound, dispense, delegate, and administer. A federal decision not to enforce does not bind them, and state rules can be stricter. The Alabama Board of Medical Examiners has already said that “under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient.” Note the first half of that sentence. Federal enforcement discretion does not make a compounded peptide FDA-approved, and it does not rewrite Alabama’s notice.

This is not only the supplier’s problem

Peptides are already everywhere in this industry, on wellness menus, in IV lounges, and in the refrigerators of practices that bought them because they were cheap. That includes licensed physicians, NPs, and PAs who should be careful about what they do that might risk their licenses. A headline like this one will push more of them to add BPC-157 to the menu this week.

A medspa that starts marketing BPC-157 injections because of this news is marketing a drug with no approved use and, as of today, no confirmed legal pathway. That practice is exposed under federal law, under its state’s medical and pharmacy rules, and under consumer protection law for any claim it makes about what the drug does.

And when regulators do come for peptide clinics, legitimate medspas get lumped in with them. Every practice that jumps the gun makes patients trust the rest of us a little less.

The decision belongs to the practitioner

If compounding is eventually allowed, every prescriber will have to decide whether to prescribe a compounded peptide that is not FDA-approved and has never been properly studied. That is a personal decision, and the risk that comes with it stays with the prescriber.

If a patient is harmed, the prescriber can face a board complaint and a civil lawsuit. A board can suspend or revoke a license. A jury will want to know what evidence supported the prescription. “The FDA chose not to enforce” is not a standard of care, and a consent form will not carry that weight. Some practitioners will decide the risk is acceptable for a particular patient. Others will not. Either way, it should be a decision made with eyes open, not one made because a supplier said peptides were about to be legal.

What legitimate legal compliance looks like right now

The current headlines do not establish any official change in policy, at least not yet. As of the date of this post, no change in practice is recommended. Wait for the published policy, then read it, including the conditions.

Watch your words and marketing. Do not call any compounded peptide “FDA-approved,” “FDA-cleared,” “fast-tracked,” or “now legal.” Do not claim it treats or cures anything. Most of the evidence is from animal studies, and regulators read your website and social media too.

Do not purchase research-use-only products. This policy will not cover them under any version that has been reported.

Verify the pharmacy. If a peptide is eventually compounded under this policy, it must come from a licensed compounding pharmacy, with pharmaceutical-grade ingredients and documentation, for an identified patient. Check the pharmacy’s license with your state board of pharmacy.

A prescription for a compounded peptide is still a prescription. The order must come from a physician, or from an NP or PA acting within their scope and any required supervision or collaboration, after a real evaluation of that patient. A templated protocol is not an evaluation. An RN or an aesthetician cannot prescribe anything in any state.

Check your state laws. Your board of medicine, nursing, and pharmacy rules still apply, whatever the FDA decides. If you practice in more than one state, check each one.

Do not lean on a consent form. Consent materials should explain that compounded drugs are not FDA-approved, that the FDA has not evaluated the finished product, and that their safety in humans is unknown. A consent form does not make an otherwise unlawful treatment lawful.

What patients should know

If a provider offers you a peptide, ask: Is this drug FDA-approved? If not, what is the rationale for injecting it? Which pharmacy compounded it, and is my name on the label? Can I see the vial? Does it say “research use only” anywhere? Who prescribed it, and did that person examine me? Look up the prescriber’s license. Look up the medical director’s license too. If anyone tells you the FDA just approved peptides, it did not, and under this process it will not.

Where The MedSpa Board stands

The MedSpa Board will be reading the policy when it is published. Until then, the law on peptides is what it was last week. The debate around peptides is fascinating and contentious, and there are reasons to hope they will be studied and shown to be effective in various different uses; however, until we have definitive data, their use will remain outside the standard of care. We will publish updates as the news unfolds.

— Kate Dee, MD

Sources & further reading

Dr. Kate Dee
Dr. Kate Dee is a Yale-educated physician and founder of the Medspa Board. She is passionate about educating people about the benefits of aesthetics treatments while avoiding the risks and shady practices.
Back to Blog

Medspa Board certification helps licensed med spas stand out by building trust, attracting high-quality clients, and showcasing verified credentials. We help consumers identify top quality medspas that emphasize safety and medical excellence.

CONTACT US

© Copyright 2026. The Medspa Board. All Rights Reserved.